Features of Clinical Course and Diagnosis of Patients with Family History of Non-Functioning Pituitary Adenomas

Z.Yu. Khalimova, D.Sh. Kholova, F.S. Khamedova, Yu.M. Urmanova, Sh.M. Safarova, D.A. Aliyeva

Abstract


The study of the incidence of non-functioning pituitary adenomas (NFPA) among relatives is important for the choice of strategy and tactics of treatment of these patients, for the development of methods for predicting the population in families with a genetic predisposition to the disease.
The objective of the study — to investigate the features of clinical symptoms, their value in the differential diagnosis in a population of patients with sporadic and family history of NFPA.
Materials and Methods. Patients with NFPA were divided into two alternatives: the first group — 50 (70.4 %) patients with environmental factors with no family history, and the second — 21 (29.6 %) patients with burdened family history, including the panmixia — 9 (2.7 %) and inbreeding — 12 (16.9 %)
patients.
Results. The patients in the population have characteristics between sporadic and hereditary NFPA both by the degree of severity of the clinical course, and by terms to identify the symptoms of the disease. In patients with familial NFPA main clinical symptoms of the disease have the following features — visual, sexual disorders, headaches, vegetative crises, menopause occur before the age of 20–25 years, and the time of diagnosis — 10–20 years; adenomas > 10 mm are being detected most often, they progress faster in giant adenomas, with more severe clinical course than in patients with non-familial NFPA.
Conclusions. The familial form of NFPA and the development of clinical symptoms at an early age should be the subject of a diagnostic screening and considered as one of the modifying factors of the disease.


Keywords


hypophysis; adenoma; diagnosis

References


Вакс В.В. Неактивные аденомы гипофиза // Нейроэндокринология: Клинические очерки / Под ред. проф. Е.И. Маровой. — Ярославль: ДИА-пресс, 1999. — С. 276-307.

Дедов И.И., Зубкова Н.А., Арбатская Н.Ю. и др. MODY тип 2: клинические и молекулярно-генетические характеристики 13 случаев заболевания. Первое описание MODY в России // Пробл. эндокринол. — 2009. — № 3. — С. 3-7.

Дедов И.И., Вакс В.В. Молекулярно-генетические аспекты патогенеза опухолей гипофиза // Актуальные проблемы нейроэндокринологии: Тез. докл 3-й Всерос. науч.-практ. конф. — М., 2003. — С. 3-5.

Кадашев Б.А. Аденомы гипофиза: клиника, диагностика, лечение. — Москва; Тверь: ООО «Триада Х», 2007. — 368 с.

Марова Е.И. Нейроэндокринология. — Ярославль, 1999. — 506 с.

Симоненко В.Б., Дулин П.А., Маканич М.А. Нейроэндокринные опухоли: руководство. — М.: ГЭОТАР-Медиа. — 2010. — 240 с.

Тюльпаков А.Н. Роль молекулярной генетики в диагностике и лечении эндокринных заболеваний. Краткая характеристика моногенных форм наследственной эндокринопатии, диагностированных в ФГУ ЭНЦ за 15-летний период (1996–2010) // Пробл. эндокринол. — 2011. — № 1. — С. 26-34.

Эндокринология / Г.М. Кроненберг, Ш. Мелмед, К.С. Полонски, Р. Ларсен / Пер. с англ. под ред. И.И. Дедова, Г.А. Мельниченко. — М.: ООО «Рид Элсивер», 2010. — 427 с.

Agha A., Thornton E., O’Kelly P. et al. Posterior pituitary dysfunction after traumatic brain injury // J. Clin. Endocrinol. Metab. — 2004. — Vol. 89. — P. 5987-5992.

Alexandr J.M., Bikkal B.M., Zervas N.T. Clinical nonfunctioning pituitary tumors are monoclonal in origin // J. Clin. Invest. — 2009. — Vol. 86, № 1. — P. 336-340.

And the Comparative Risk Assessment Collaborating Group Selected major risk factor and global and regional burden / M. Ezzati, A. Lopez, A. Rodgers et al. // Lancet. — 2002. — Vol. 360. — P. 1347-1360.

Arafah B.M., Nasrallan M.R. Pituitary tumors: pathophisiology, clinical manifestations and management // Endocrinol. Relaf. Cancer. — 2001. — Vol. 4. — P. 287-305.

Beckers A. C.D. Pituitary adenomas // Graph. Med. Ltd. — 2007. — P. 367-481.

Beeckers A., Daly A.F. The clinical, pathological, and genetic features of familial isolated pituitary adenomas // Europ. J. Endocrinol. — 2007. — Vol. 157, № 4. — P. 371-382.

Chahal H.S. Familial isolated pituitary adenomas // Turop. Endocrinol. — 2009. — Vol. 1. — P. 2638-2640.

Daly A.F., Vanbellinghev J.F., Rhoo S.K. et al. Aryl hydrocarbon receptor-interacting protein gene vutations in familial isolated pituitary adenomas: analysis in 73 families // J. Clin. Endocrinol. Metab. — 2007. — Vol. 92, № 5. — P. 1917-1919.

Doherty G.M., Thompson N.W. Multiple endocrine neoplasma type 1: duodenopancreatic tumors // J. Surg. Oncol. — 2005. — Vol. 89. — P. 143-150.

Krages W., Schaaf L., Dralle H., Bjehm B.O. Clinical and molecular diagnosis of multiple endocrine neoplasma type 1 // Langenbeck. Arch. Surg. — 2002. — Vol. 386. — P. 547-552.

Marini F., Falchetti A., Monte F. Del. et al. Multiple endocrine neoplasma type 1 // Orphanet. J. Rare. — 2006. — Vol. 2. — P. 1-38.

Mekted S. Update in pituitary disease // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93, 2. — P. 331-338.

Ruentes F., Notkola J.-L., Shemeikka S. et al. Familial aggregations of blood pressure in a population — based family study in eastern Finland // XX Congress of the Europen society of Cardiology. — 1998. — Abstr. 563.

Szarfman A., Tonning J.M., Levine J.G., Doraiswamy P.M. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study // Pharmacotherapy. — 2006. — Vol. 26. — P. 748-758.

Villa C., Magri F., Morbini P. et al. Silent familial isolated pituitary adenomas: Histopathological and Clinical Case Report // Endocrine pathology. — 2008. — Vol. 19, № 1. — P. 40-46.

Zhu X., Lin C.R., Prefontaine G.G., Tollkuhn J., Rosenfeld M.G. Genetic control of pituitary development and hypopituitarism // Curr. Opin. Genet. Dev. — 2005. — Vol. 15. — P. 332-340.




DOI: https://doi.org/10.22141/2224-0721.4.52.2013.84383

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru